Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psychiatric diseases

- PMLiVE

Boehringer posts solid first half as business revamp beds in

Jardiance helped to boost sales

Diagnosing the lag in neuropsychiatric treatments

The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop...

Blue Latitude Health

- PMLiVE

Boehringer taps Korea’s Bridge for Ofev follow-up

Latest in a string of in-licensing deals

- PMLiVE

Amgen gets block on sales of Repatha rival in Germany

Part of ongoing battle with Sanofi and Regeneron

- PMLiVE

Boehringer tests speech as early warning for CNS diseases

Company extends foray into digital health innovation

The role of brain health in treating MS

Blue Latitude Health speaks to Professor Gavin Giovannoni, key opinion leader and Chair of Neurology, Barts and The London School of Medicine and Dentistry, about his theories on brain health,...

Blue Latitude Health

- PMLiVE

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Strengthens existing relationship

- PMLiVE

FDA fast-tracks Jardiance for heart failure review

Would challenge Novartis' Entresto

- PMLiVE

AmyPore gets EU backing for Alzheimer’s and Parkinson’s therapy

Novel chimeric peptide ready to start clinical trials

- PMLiVE

Boehringer eyes rare disease use for respiratory blockbuster

Would help support respiratory franchise

- PMLiVE

Bicycles Therapeutics enters dementia discovery with venture capital fund

Ambitious UK biotech expands research scope

- PMLiVE

With Spiriva under pressure, Boehringer moves to bolster pipeline

Forges alliance with PureTech Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links